Preclinical studies are more of a concern than clinical studies, where standardized reporting procedures exist and where there is more rigorous design and oversight [1] . The use of animal models in preclinical work seems to be an area where problems seem to crop up more often. The use of different strains of animals, for example, can be a source of disagreement. Preclinical work may be an area where rapid progress can be made.
Obviously, something must be done, and it is being done. The NIH is developing a number of initiatives, some of which will become mandatory in NIH sponsored training programs. There will be specific training opportunities with an emphasis on good experimental design. A checklist will be developed for reviewers and evaluators that address experimental procedures such as sample size calculations, randomization, blinding and so forth. Access to raw data and increased transparency will be addressed. Other groups in the scientific community will have to participate as well. These groups will include journals, private granting agencies, various review panels, and others.
Journal of Drug and Alcohol Research (JDAR) has not had a problem with irreproducible results, but it is not a problem that can be ignored. I write this letter because this is a significant issue that is not going away. Correcting this problem can only be a good thing. This journal will support efforts to improve reproducibility, and will judiciously follow recommendations made by responsible groups. It seems reasonable to suggest that readers and submitters follow this topic and the recommendations from the NIH and elsewhere.
